Search
Upstream Bio Inc
UPBAdd to Watchlist
6.310USD
-0.260-3.96%
Close 07-31 16:00（ET）Quotes delayed by 15 min
343.39MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Upstream Bio Inc is 7.78, ranking 272 out of 385 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 75.00 and a low of 35.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
43.500
Target Price
+589.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Upstream Bio Inc
UPB
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Upstream Bio Inc's expected revenue for the next quarter?
Upstream Bio Inc's expected revenue is 430.71K.
What is Upstream Bio Inc's price target?
Analysts forecast that Upstream Bio Inc's price target is USD 43.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 35.00.
How have Upstream Bio IncUPB's recent earnings per share performed?
The market expectation was USD -0.75, while Upstream Bio IncUPB's earnings per share (EPS) for the previous quarter was USD -2.66. EPS for the next quarter is expected at USD -0.76.
What is the analyst rating for Upstream Bio Inc?
Based on the ratings of Upstream Bio Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.